Table 2.

Individual data regarding PNa kinetics-related variables, after DDAVP administration

Patient No.SexAge (yr)PNabef (mmol/L)DDAV-Related Variables and Volume of Hypotonic/Electrolyte-Free Fluids after DDAVPHypotonic Fluids/ Electrolyte-Free Fluid Volume after DDAVP Administration (ml)bPNa Levels 24 and 48 h after Ti
DDAVP Doses (n)Total DDAVP dose (µg)Time Span for Ti to DDAVP (h)aΔPNa after DDAVP (mmol/L)cPNa Correction Rate (mmol/L per hour)dUrine Output (ml/h)UNa+UK (mmol/L)eUosm (mOsmol/L)fΔ24 (mmol/L)gΔ48 (mmol/L)h
1Male5111528242500/250080.29NA78390814
2Female6111626251750/150060.48104NANA818
3Male611193461500/15004−0.07NA10334474
4Female761191221500/ 05−0.245452188126
5Male5412438236500/55006−0.2333NANA126
6Male5512722i52000/200050.0914231150812
7Female781281223250/2503−0.1317667216107
8Male6211328301500/150080.26NANANA1016
9Female771121210250/25030.108370272413
10Male541272855500/550040NA4940478
11Female51119125500/25040.4636NANA1016
12Female571151212350/35060.3663232031017
13Female461314816750/7509−0.06NA4314797
14Male8214218143000/300015−0.65NA241351411
15Female711221429250/2503045132141411
16Female871192810750/7502−0.0425NANA1113
17Male401271223250/2505−0.21158NANA1618
18Female571183125600/6007−0.04145918614
19Male4712031241300/3005−0.171171284810
20Male30130289500/50050.08128303091317
Median (IQR) or n57
(51, 74.8)119.5
(116.5, 127)2
(1, 2.8)8
(2, 8)13
(5.3, 23)1000 (500, 1875)/
750 (388, 1938)5
(4, 6.8)−0.02
(−0.16, 0.22)93.5
(43, 143)46
(23.8, 72)209
(149, 318)10
(8, 12)11.5
(7, 16)
  • PNAbef, last recorded PNa before DDAVP.

  • a Time elapsed between Ti and the first DDAVP administration.

  • b Total volume of hypotonic and electrolyte-free fluids infused after DDAVP administration.

  • c Calculated as the difference between the maximum and the minimum PNa levels recorded after the first DDAVP administration, and within 24 hours of the administration.

  • d The PNa correction rate after the first DDAVP administration was determined as the difference between the PNa level recorded 24 hours after the first DDAVP administration, or before a repeat administration if it occurred <24 hours after the first injection, and the PNa level evaluated within 2–6 hours after the first DDAVP administration with respect to the time elapsed during this period.

  • e Sum of urine sodium (UNa) and urine potassium (UK) levels on sampling after DDAVP administration.

  • f Urine osmolarity (Uosm) determined after DDAVP administration, calculated as follows: Uosm=2×(UNa+UK)+Uurea, where Uurea represents urinary urea nitrogen.

  • g Δ24 was defined as the difference between PNai and the PNa level assessed 24 hours after DDAVP administration.

  • h Δ48 was defined as the difference between PNai and the PNa level assessed 48 hours after DDAVP administration.

  • i An additional 10 µg was administered via the intranasal route.